Shares of HUTCHMED (China) Limited (LON:HCM - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 233.96 ($3.17) and traded as low as GBX 212 ($2.87). HUTCHMED shares last traded at GBX 224 ($3.03), with a volume of 100,443 shares.
HUTCHMED Price Performance
The stock has a market capitalization of £2.44 billion, a PE ratio of -57.43 and a beta of 0.76. The firm's fifty day moving average price is GBX 214.95 and its two-hundred day moving average price is GBX 232.75. The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.97.
HUTCHMED Company Profile
(
Get Free Report)
We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.
We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.
HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.